Klotho Neurosciences CEO on why Klotho’s role in aging makes it more than a longevity gene – and why ALS may prove its most telling test.
Klotho has long fascinated scientists of aging. First identified in mice where overexpression extended lifespan and loss of function led to premature decline, Klotho exerts influence across multiple systems – kidney, brain, muscle, even cardiovascular tissue – and its decline with age has made it a compelling candidate in the search for therapeutic ways to sustain healthspan.
From this biology emerged Klotho Neurosciences, a company aiming to turn that fascination into clinical reality. Its lead program, KLTO-202, delivers Klotho via gene therapy to protect neurons and preserve motor function in amyotrophic lateral sclerosis (ALS) – a disease in which biology and aging intersect with devastating clarity. For a company that sits squarely in the growing overlap between neuroscience and geroscience, ALS is not just a target, but a proving ground for the wider promise of Klotho biology.
Longevity.Technology: Klotho has become something of a signature presence in aging biology; it is implicated in neurology, metabolism, kidney function and cognition, and yet it refuses to conform to a single narrative. While the notion of a ‘longevity gene’ can sound dangerously close to marketing shorthand, the data on Klotho’s neuroprotective and anti-inflammatory properties continue to deepen. What’s striking is the shift in tone from promise to pragmatism: rather than chasing lifespan headlines, Klotho Neurosciences is tackling ALS – a hard, measurable disease with clear outcomes. That’s where longevity science now finds its footing; not in chasing years, but in restoring the capacities that make them worth living. We sat down with Klotho Neuro founder and CEO Dr Joseph Sinkule to find out more.
From aging biology to clinical reality
Dr Joseph Sinkule believes the future of neurodegenerative disease treatment may lie not in silencing damaged pathways, but in restoring the body’s own defences against decline. Klotho, he argues, is central to that repair system – a protein that protects neurons, mitigates inflammation and clears cellular debris as biological systems age.
“Aging is both chronologic and biologic,” he explains, adding that its cumulative effects lay the groundwork for neurodegeneration, including conditions such as ALS. “Klotho is protective and corrective of many of these pathologies of aging and neurologic diseases like ALS. In ALS, neurons die and the neuronal connections with the muscle at the neuromuscular junction become dysfunctional,” he says. “If we can administer a gene therapy delivering the Klotho protein at therapeutic levels to neurons, dendrites, and the upper and lower motor cortex regions of the body, we should positively affect the transmission of signals from the brain to the muscles.”
Translating preclinical promise
Klotho Neurosciences is using gene therapy to address specific, measurable disease mechanisms. Its lead candidate, KLTO-202, employs an adeno-associated virus (AAV) vector to deliver the Klotho gene directly into affected neural tissues – a strategy the company hopes will translate protective effects from animal studies to human trials.
“Mouse and human s-KL proteins are nearly identical, and both perform equally well in established models of ALS, Alzheimer’s and Parkinson’s disease,” Sinkule says. “Based on non-human primate biodistribution data, we have chosen AAV vectors that carry the s-KL gene sequence to the regions affected in these diseases, and we are confident that the biology, pharmacology and efficacy will carry over to our planned clinical trials.”
Targeting disease, improving healthspan
Klotho has been studied in multiple systems – brain, kidney, muscle, even cardiovascular tissue – but Sinkule says the company’s therapeutic ambitions are grounded in clinical realism rather than abstract longevity. Developing a product to “extend lifespan” directly, he explains, would be scientifically interesting but practically impossible.
“It would be very difficult to prove that administration of a medical product can result in a statistically significant difference in improvement of lifespan over a control group not getting the product,” he says. “Such studies would take decades and require vast cohorts, making them impractical to fund or run.”
Instead, he positions Klotho Neurosciences firmly in the territory where age-related disease meets measurable outcome. “Our path targets ALS, other neurodegenerative diseases and diseases associated with aging,” he explains. “These include muscle wasting, bone loss, weight loss, cancers, kidney disease and cardiovascular pathologies, where Klotho has already provided positive data. If we can have an impact on one or two of these diseases, we will not only extend lifespan, but also provide an improved healthspan as well.”
Epigenetics and the Klotho Clock
Many in the longevity community talk about targeting aging itself rather than individual diseases, but Sinkule sees those goals as overlapping rather than opposing. “The data show that if you ‘knock out’ or mutate the Klotho gene, the animals die a very rapid death with symptoms and pathologies very much like humans who die of old age,” he says. “If you amplify the number of Klotho gene copies, give the Klotho protein directly, or use gene therapy to continually express the protein, the treated animals live 25 to 35 percent longer than the average lifespan of normal healthy mice, dogs and non-human primates.”
He explains that elevated Klotho protein levels are known to extend lifespan, yet the problem lies in biology’s own timekeeping. “As we get older, Klotho protein levels fall,” he says. “The problem is epigenetic changes that occur with aging. DNA methylation can silence the Klotho gene by hypermethylating its promoter region, preventing protein production.”
Rather than attempting to demethylate directly, which Sinkule describes as “quite toxic and nonspecific,” Klotho Neurosciences is using an AAV vector to deliver the functional gene into cells, ensuring long-term protein expression. “Our approach is to use the AAV vector to infect cells and produce the Klotho protein in the cytoplasm, providing a long-term supply of the protein to the body,” he says.
This focus on epigenetics has led the company to develop what it calls the Klotho Clock, a blood test that quantifies methylation levels of the Klotho promoter. “We are developing an epigenetic blood test to quantitate the level of methylation of the human Klotho promoter in a subject,” Sinkule explains. “We will use this test in our clinical trials to balance the rapid agers and the slower agers in both arms of our studies.”
He adds that this test could ultimately serve a predictive role, identifying individuals whose biological aging is outpacing their chronological years. “There may be a point in time when, at 40 or 50 years of age, one gets a Klotho Clock blood test to determine biological age versus chronological age and, if a subject is aging rapidly, we may be able to slow it down with a dose of our Klotho gene therapy product.”
Focus and partnerships
Recent headlines have also centred on Klotho Neurosciences’ letter of intent to acquire certain assets from Turn Biotechnologies, accompanied by mention of a potential $300 million global pharma partnership. The company later confirmed that the LOI had expired – a turn of events that raised some eyebrows in the longevity community, but Sinkule is quick to clarify the rationale.
“Following a comprehensive review, we determined that our long-term priorities were not fully aligned with the proposed transaction,” he tells us. “Our core focus is on advancing the Klotho development and research programs.”
With KLTO-202 advancing toward human trials, the company’s priority is depth rather than breadth. “The focus now is to execute on our lead programs and build the data needed for both regulatory and investor confidence,” he explains, noting that strategic partnerships remain very much on the table – but only when they serve the central goal of bringing Klotho-based therapies to patients.
A masterplan for a master gene?
Looking ahead, Sinkule remains both pragmatic and idealistic. “In 10 years I’ll be over 80 years old,” he says wryly, “and I hope that the scientific community will acknowledge Dr Makoto Kuro-o by awarding him the Nobel Prize in Medicine for his discovery of the Klotho gene and its protective effects in all mammals on Earth.”
Sinkule refers to Klotho as a “master gene,” one that regulates a web of downstream pathways involved in resilience, repair and metabolic balance. “These pleiotropic activities provide us a platform for developing multiple medical products for multiple therapeutic indications, many of which involve diseases of aging,” he says. The expanding literature seems to support that view – more than 4,000 scientific publications and counting, with interest accelerating as geroscience matures into a translational discipline.
“Klotho is absolutely a longevity factor,” he says. “But it alone may not be enough to extend a healthy lifespan. If one exercises to stay fit, eats right, gets a good night’s sleep, has a good genomics and proteomics profile, lives life in moderation and maintains a relatively normal Klotho tissue level, Klotho would be considered a strong contributing longevity factor.”
